Clinical Trials › NCT06700343
RecruitingPhase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Sponsored by Amgen
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 444
Target enrollment
17
U.S. states
Jan 2025
Start date
Dec 2027
Expected completion
Interventions / Treatments
Ocrelizumab (US)Ocrelizumab (EU)ABP 692
Conditions studied
Relapsing-remitting Multiple Sclerosis (RRMS)
Where this trial is running (25 sites)
Florida4 sites
Boca Raton · Naples · Rockledge · +1 more
Colorado2 sites
Basalt · Fort Collins
Michigan2 sites
Detroit · Farmington
New Jersey2 sites
Edison · Paramus
Ohio2 sites
Columbus · Dayton
Tennessee2 sites
Knoxville · Nashville
Alabama1 site
Mobile
Arizona1 site
Scottsdale
California1 site
Carlsbad
Connecticut1 site
New Haven
Hawaii1 site
Honolulu
Kansas1 site
Kansas City
New Mexico1 site
Albuquerque
North Carolina1 site
Winston-Salem
South Carolina1 site
Greenville
Texas1 site
Frisco
Wisconsin1 site
Milwaukee
Participating MS centers on MS Buddy (12)
Michigan Institute For Neurological Disorders MIND
Farmington Hills, MI
Farmington Hills, MI
Mountain Neurological Research Center
Basalt, CO
Basalt, CO
Hope Neurology, PLLC
Knoxville, TN
Knoxville, TN
Knight Neurology
Rockledge, FL
Rockledge, FL
Lone Star Neurology
Frisco, TX
Frisco, TX
Hackensack UMC Multiple Sclerosis Center
Paramus, NJ
Paramus, NJ
Premier Neurology, PC
Greenville, SC
Greenville, SC
Hasbani Neurology
New Haven, CT
New Haven, CT
MS centers in Florida
Compare treatment centers near a trial site — patient experience, providers, and care ratings.
View Florida centersMore Phase 3 trials
Browse all Phase 3 MS trialsCheck out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
